Barinthus Biotherapeutics plc
BRNS
$0.74
-$0.02-2.49%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 3.92M | 271.00K | 374.00K | -308.00K | 7.95M |
| Gross Profit | -3.92M | -271.00K | -374.00K | 308.00K | -7.95M |
| SG&A Expenses | 7.03M | 2.38M | 1.50M | 5.15M | 15.64M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -5.00K | -46.00K | -434.00K | -72.00K | -13.00K |
| Total Operating Expenses | 10.91M | 5.78M | 4.88M | 10.23M | 22.24M |
| Operating Income | -10.91M | -5.78M | -4.88M | -10.23M | -22.24M |
| Income Before Tax | -10.62M | -5.55M | -11.16M | -14.64M | -21.15M |
| Income Tax Expenses | -23.00K | -16.00K | -57.00K | -71.00K | -25.00K |
| Earnings from Continuing Operations | -10.60M | -5.53M | -11.10M | -14.57M | -21.13M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 19.00K | 3.00K | 13.00K | 5.00K | 2.00K |
| Net Income | -10.58M | -5.53M | -11.09M | -14.57M | -21.12M |
| EBIT | -10.91M | -5.78M | -4.88M | -10.23M | -22.24M |
| EBITDA | -10.69M | -5.52M | -4.57M | -10.13M | -21.04M |
| EPS Basic | -0.26 | -0.14 | -0.27 | -0.36 | -0.52 |
| Normalized Basic EPS | -0.16 | -0.08 | -0.07 | -0.15 | -0.33 |
| EPS Diluted | -0.26 | -0.14 | -0.27 | -0.36 | -0.52 |
| Normalized Diluted EPS | -0.16 | -0.08 | -0.07 | -0.15 | -0.33 |
| Average Basic Shares Outstanding | 40.85M | 40.85M | 40.83M | 40.66M | 40.34M |
| Average Diluted Shares Outstanding | 40.85M | 40.85M | 40.83M | 40.66M | 40.34M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |